Clinical Trial

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-16; most recent amendment 2026-07-07.
Status change: Not Yet Recruiting → Recruiting 2025-09-24
Trial Details
NCT Number NCT07083011
Lead Sponsor Mayo Clinic
Conditions Heart Failure With Preserved Ejection Fraction
Enrollment 35 participants
Start Date 2025-11-01
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-08